Altimmune (NASDAQ:ALT) Upgraded at The Goldman Sachs Group

Altimmune (NASDAQ:ALT - Get Free Report) was upgraded by research analysts at The Goldman Sachs Group to a "strong sell" rating in a research note issued on Thursday, MarketBeat Ratings reports.

A number of other brokerages also recently issued reports on ALT. HC Wainwright reissued a "buy" rating and set a $12.00 target price on shares of Altimmune in a research note on Friday, June 27th. JMP Securities cut their target price on Altimmune from $25.00 to $15.00 and set a "market outperform" rating for the company in a research note on Thursday. William Blair reissued a "market perform" rating on shares of Altimmune in a research note on Friday, June 27th. Finally, Wall Street Zen downgraded Altimmune from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $18.20.

Altimmune Trading Down 7.2%

Altimmune stock opened at $4.40 on Thursday. Altimmune has a twelve month low of $2.90 and a twelve month high of $11.16. The stock has a 50 day moving average of $5.65 and a two-hundred day moving average of $5.87. The stock has a market capitalization of $356.88 million, a price-to-earnings ratio of -3.49 and a beta of 0.47.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.09. Altimmune had a negative return on equity of 65.44% and a negative net margin of 451,200.00%. The company had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.00 million. During the same period last year, the firm earned ($0.34) EPS. Equities analysts predict that Altimmune will post -1.35 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC lifted its stake in shares of Altimmune by 214.2% in the first quarter. GAMMA Investing LLC now owns 6,745 shares of the company's stock worth $34,000 after acquiring an additional 4,598 shares in the last quarter. Magnus Financial Group LLC bought a new stake in Altimmune in the first quarter valued at about $50,000. Headland Capital LLC bought a new stake in Altimmune in the first quarter valued at about $50,000. Geneos Wealth Management Inc. bought a new stake in Altimmune in the first quarter valued at about $50,000. Finally, Virtus ETF Advisers LLC bought a new stake in Altimmune in the fourth quarter valued at about $60,000. Institutional investors and hedge funds own 78.05% of the company's stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.